Literature DB >> 33040364

Adult-onset eosinophilic airway diseases.

Koichiro Asano1, Shigeharu Ueki2, Mayumi Tamari3, Yoshimasa Imoto4, Shigeharu Fujieda4, Masami Taniguchi5.   

Abstract

Eosinophilic airway inflammation is one of the cardinal features of allergic airway diseases such as atopic asthma and allergic rhinitis. These childhood-onset conditions are mediated by allergen and allergen-specific IgE and often accompanied by other allergic diseases including food allergy and eczema. They can develop consecutively in the same patient, which is referred to as an allergic march. In contrast, some phenotypes of asthma, nonsteroidal anti-inflammatory drugs-exacerbated airway disease (N-ERD), chronic rhinosinusitis with nasal polyps (CRSwNP)/eosinophilic CRS and allergic bronchopulmonary aspergillosis/mycosis (ABPA/ABPM) are adult-onset airway diseases, which are characterized by prominent peripheral blood eosinophilia. Most of these conditions, except for ABPA/ABPM, are nonatopic, and the coexistence of multiple diseases, including an adult-onset eosinophilic systemic disease, eosinophilic granulomatosis with polyangiitis (EGPA), is common. In this review, we focus on eosinophil biology, genetics and clinical characteristics and the pathophysiology of adult-onset eosinophilic asthma, N-ERD, CRSwNP/eosinophilic CRS, ABPA/ABPM and EGPA, while exploring the common genetic, immunological and pathological conditions among these adult-onset eosinophilic diseases.
© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Entities:  

Keywords:  asthma; eosinophils; extracellular trap cell death; thymic stromal lymphopoietin

Mesh:

Year:  2020        PMID: 33040364     DOI: 10.1111/all.14620

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  9 in total

1.  Serum Cytokines Usefulness for Understanding the Pathology in Allergic Bronchopulmonary Aspergillosis and Chronic Pulmonary Aspergillosis.

Authors:  Yuya Ito; Takahiro Takazono; Yasushi Obase; Susumu Fukahori; Nobuyuki Ashizawa; Tatsuro Hirayama; Masato Tashiro; Kazuko Yamamoto; Yoshifumi Imamura; Naoki Hosogaya; Chizu Fukushima; Yoshitomo Morinaga; Katsunori Yanagihara; Koichi Izumikawa; Hiroshi Mukae
Journal:  J Fungi (Basel)       Date:  2022-04-23

Review 2.  Therapeutic Potential for Intractable Asthma by Targeting L-Type Amino Acid Transporter 1.

Authors:  Keitaro Hayashi; Osamu Kaminuma
Journal:  Biomolecules       Date:  2022-04-08

Review 3.  Therapeutic Strategies of Biologics in Chronic Rhinosinusitis: Current Options and Future Targets.

Authors:  Junhu Tai; Munsoo Han; Tae Hoon Kim
Journal:  Int J Mol Sci       Date:  2022-05-15       Impact factor: 6.208

4.  Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status.

Authors:  Shigeharu Fujieda; Shoji Matsune; Sachio Takeno; Nobuo Ohta; Mikiya Asako; Claus Bachert; Tomoyuki Inoue; Yoshinori Takahashi; Hiroyuki Fujita; Yamo Deniz; Paul Rowe; Benjamin Ortiz; Yongtao Li; Leda P Mannent
Journal:  Allergy       Date:  2021-06-04       Impact factor: 14.710

5.  Case Report: Eosinophilic Bronchiolitis With Eosinophil ETosis in Mucus Plugs Successfully Treated With Benralizumab.

Authors:  Hisashi Sasaki; Jun Miyata; Akiko Irie; Ayako Kuwata; Yuji Kouzaki; Shigeharu Ueki; Akihiko Kawana
Journal:  Front Pharmacol       Date:  2022-01-13       Impact factor: 5.810

Review 6.  Eosinophilic Asthma, Phenotypes-Endotypes and Current Biomarkers of Choice.

Authors:  Konstantinos Porpodis; Ioanna Tsiouprou; Apostolos Apostolopoulos; Polyxeni Ntontsi; Evangelia Fouka; Despoina Papakosta; Harissios Vliagoftis; Kalliopi Domvri
Journal:  J Pers Med       Date:  2022-06-30

Review 7.  Chronic Rhinosinusitis, S. aureus Biofilm and Secreted Products, Inflammatory Responses, and Disease Severity.

Authors:  Gohar Shaghayegh; Clare Cooksley; Mahnaz Ramezanpour; Peter-John Wormald; Alkis James Psaltis; Sarah Vreugde
Journal:  Biomedicines       Date:  2022-06-09

8.  Cinnamomum cassia (L.) J.Presl Alleviates Allergic Responses in Asthmatic Mice via Suppression of MAPKs and MMP-9.

Authors:  Je-Oh Lim; Yun Hee Kim; Ik Soo Lee; Woong-Il Kim; Se-Jin Lee; So-Won Pak; In-Sik Shin; Taesoo Kim
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

Review 9.  Immune mechanisms induced by sublingual immunotherapy in allergic respiratory diseases.

Authors:  Umut Gazi; Nerin Nadir Bahceciler
Journal:  Clin Exp Immunol       Date:  2022-09-29       Impact factor: 5.732

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.